Clarity, ImaginAb team to develop theranostic agents

By staff writers

July 21, 2020 -- Radiopharmaceutical firm Clarity Pharmaceuticals and imaging agent developer ImaginAb are collaborating to develop new targeted theranostic products for a range of cancer types.

Specifically, the companies said they will use Clarity's copper chelators to develop minibody and cys-diabody radiopharmaceutical products that utilize copper-64 for diagnosis and copper-67 for therapy.

ImaginAb has previously coupled radioisotopes with minibodies and cys-diabodies for PET imaging of molecular targets. The partnership marks ImaginAb's entry into the field of targeted radiotherapy, according to the vendor.

Copyright © 2020

To read this and get access to all of the exclusive content on create a free account or sign-in now.

Member Sign In:
MemberID or Email Address:  
Do you have a password?
No, I want a free membership.
Yes, I have a password:  
Forgot your password?
Sign in using your social networking account:
Sign in using your social networking